Lundbeck CFO begins work

The Danish pharmaceutical firm’s new chief financial officer, who took over after Anders Götzsche announced his departure last year, has begun his work before schedule. (Corrected)

Photo: Thomas Borberg/Politiken/Ritzau Scanpix

by christian bundgaard, translated by daniel pedersen

The article is being updated

(Correction: A previous version of this article stated that Lundbeck had just announced the appointment of Joerg Hornstein. This was incorrect, and the article has been updated to reflect that today is his first day at the firm. MedWatch apologizes for the mistake.)

In a post on Linkedin, Lundbeck writes that Joerg Hornstein has begun working as the company’s chief financial officer before his original starting date on September 1, which was reported when he was announced as Anders Götzsche’s replacement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

ALK to exit Turkish market: "It's bad business if all we get is peanuts"

ALK's Turkish workforce will have look for employment elsewhere | Foto: ALK / PR

A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.

Genmab postpones crucial cancer candidate decision following Abbvie exit

Foto: PR / Genmab

For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.

Genmab says new arbitration builds on a straightforward question

Foto: Joost Melis / Genmab / PR

”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.

Top news from MedWatch this week

Miss anything?

Analyst: Upgraded ALK sales guidance could still be beaten

Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.

Further reading

Related articles